2 results
Approved WMOCompleted
The objective of this study is to confirm the safety and effectiveness of the Reducer when used in patients with refractory angina who demonstrate evidence of reversible ischemia.
Approved WMOCompleted
Primary Objectives* To compare the pathologic complete response (pCR) rate of neoadjuvant nivolumab + NKTR-214 to Standard of Care (SOC, no neoadjuvant therapy) in all randomized participants* To compare the event-free survival (EFS) of neoadjuvant…